“The long-awaited era of disease-modifying therapy for Alzheimer’s disease has finally arrived and will substantially impact how the disease is perceived and managed, although these new treatments will pose challenges for equitable access. The drugs closest to widespread clinical implementation are lecanemab and donanemab—intravenous monoclonal antibodies that remove β-amyloid plaques from the brain and can slow cognitive and functional decline.”

Donanemab appears to be the ‘easier’ choice. MMSE 20-28, Monthly Infusion (vs q2Wk), Stop when Amyloid PET is negative. Probably need to get APOE on these patients.
https://doi.org/10.1016/S1474-4422(23)00274-0

Contact Dr. Varipapa’s office if you are interested in exploring this option.